Press Releases

Date	Title
September 17, 2021	Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
September 9, 2021	Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
August 12, 2021	William Guyer to Join Corcept as Chief Development Officer
July 29, 2021	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 22, 2021	Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 12, 2021	Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
June 22, 2021	Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 15, 2021	Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 10, 2021	Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
May 6, 2021	Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results